ROCO
6661
Market cap13mUSD
Jul 09, Last price
18.25TWD
1D
2.53%
1Q
-1.08%
IPO
-29.86%
Name
Welgene Biotech Co Ltd
Chart & Performance
P/E
319.78
P/S
1.13
EPS
0.06
Div Yield, %
—
Shrs. gr., 5y
2.28%
Rev. gr., 5y
-1.14%
Revenues
376m
+16.55%
Net income
1m
+20.14%
CFO
35m
-37.11%
Dividend
Mar 16, 20230.18144 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysis, qPCR verification, nucleic acid extraction and quality control, LCM single cell experimentation, and intricate bioinformatics analysis. A key offering in their portfolio is Cytoscan, an array-based comparative genomic hybridization (CGH) solution. Beyond services, Welgene Biotech also supplies essential laboratory products, including various reagents, consumable items, and specialized instruments, alongside dedicated software solutions. Established in 2003, the company operates from its headquarters in Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||